March 12 (Reuters) - Redhill Biopharma Ltd 2RHy.F:
REDHILL BIOPHARMA ADVANCES ITS GROUNDBREAKING LATE-STAGE CROHN'S DISEASE PROGRAM BUILDING ON STATISTICALLY SIGNIFICANT POSITIVE RHB-104 PHASE 3 RESULT
Further company coverage: [2RHy.F]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.